A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 06 Jun 2017 Results assessing the efficacy and safety of combined use of sorafenib and yttrium-90 resin microspheres in patients with advanced hepatocellular carcinoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 08 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.